Pàgina inicial > Resultats de la cerca: Cervantes, A.
  Consells de cerca
Cerca simple
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Dipòsit Digital de Documents de la UAB 19 registres trobats  anterior11 - 19  anar al registre: La cerca s'ha fet en 0.00 segons. 
11.
9 p, 1023.2 KB Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain : results of a subgroup analysis of the phase 3 RECOURSE trial / Longo Muñoz, Federico (Hospital Universitario Ramón y Cajal (Madrid)) ; Argilés Martínez, Guillem (Hospital Universitari Vall d'Hebron) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Cervantes, Andrés (Universitat de València) ; Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ; Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Gil Calle, S. (Hospital Regional Universitario Carlos Haya (Málaga)) ; Mizuguchi, Hirokazu (Taiho Oncology) ; Carrato, Alfredo (Hospital Universitario Ramón y Cajal (Madrid)) ; Limón, María Luisa (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; García Carbonero, Rocio (Hospital Universitario 12 de Octubre (Madrid)) ; Universitat Autònoma de Barcelona
TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. [...]
2017 - 10.1007/s12094-016-1528-7
Clinical & Translational Oncology, Vol. 19, Issue 2 (February 2017) , p. 227-235  
Registre complet -
12.
6 p, 1.4 MB Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients / Sclafani, Francesco (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Chau, Ian (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Cunningham, David (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Lampis, Andrea (The Institute of Cancer Research. Department of Molecular Pathology) ; Hahne, Jens Claus (The Institute of Cancer Research. Department of Molecular Pathology) ; Ghidini, Michele (The Institute of Cancer Research. Department of Molecular Pathology) ; Lote, Hazel (The Institute of Cancer Research. Department of Molecular Pathology) ; Zito, Domenico (The Institute of Cancer Research. Department of Molecular Pathology) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Glimelius, Bengt (University of Uppsala. Genetics and Pathology, Experimental and Clinical Oncology. Department of Immunology) ; Cervantes, Andrés (University of Valencia. Biomedical Research Institute INCLIVA. Department of Haematology and Medical Oncology) ; Begum, Ruwaida (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; De Castro, David Gonzalez (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Wilson, Sanna Hulkki (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Peckitt, Clare (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Eltahir, Zakaria (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Wotherspoon, Andrew (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Tait, Diana (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Brown, Gina (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Oates, Jacqueline (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Braconi, Chiara (The Institute of Cancer Research. Department of Cancer Therapeutics) ; Valeri, Nicola (The Institute of Cancer Research. Department of Molecular Pathology) ; Universitat Autònoma de Barcelona
Analysis of a polymorphism in mature microRNA-608 (rs4919510) in rectal cancer patients enrolled in a randomized phase II clinical trial identified patient subpopulations who might benefit from the use of an intensified neo-adjuvant treatment strategy with Cetuximab. [...]
2016 - 10.1093/carcin/bgw073
Carcinogenesis, Vol. 37 (july 2016) , p. 852-857  
Registre complet - Creative Commons
13.
9 p, 306.4 KB Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer / Elez, Elena (Vall d'Hebron Institut d'Oncologia) ; Hendlisz, A. (Institut Jules Bordet (Belgium)) ; Delaunoit, T. (Centres Hospitaliers Jolimont (Belgium)) ; Sastre Valera, Javier (Hospital Clínico San Carlos (Madrid)) ; Cervantes, Andrés (Instituto de Investigación Sanitaria INCLIVA (València, Comunitat Valenciana)) ; Varea, R. (Eli Lilly and Company (Spain)) ; Chao, G. (Eli Lilly and Company (USA)) ; Wallin, J. (Eli Lilly and Company (Suècia)) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
This single-arm phase II study investigated the EGFR monoclonal antibody necitumumab plus modified FOLFOX6 (mFOLFOX6) in first-line treatment of locally advanced or metastatic colorectal cancer (mCRC). [...]
2016 - 10.1038/bjc.2015.480
British Journal of Cancer, Vol. 114 (February 2016) , p. 372-380  
Registre complet - Creative Commons
14.
6 p, 225.1 KB Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer : results of the EXPERT-C trial / Sclafani, Francesco (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Chau, Ian (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Cunningham, David (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Peckitt, C. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Lampis, Andrea (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Hahne, Jens Claus (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Braconi, Chiara (The Institute of Cancer Research. Division of Cancer Therapeutics (UK)) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Glimelius, B. (University of Uppsala. Department of Immunology, Genetics and Pathology (Sweden)) ; Cervantes, Andrés (Universitat de València. Departament d'Hematologia i Oncologia Mèdica) ; Begum, Ruwaida (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; González De Castro, David (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Hulkki Wilson, Sanna (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Eltahir, Zakaria (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Wotherspoon, Andrew (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Tait, D. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Brown, Gina (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Oates, J. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Valeri, Nicola (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Universitat Autònoma de Barcelona
Lethal-7 (let-7) is a tumour suppressor miRNA which acts by down-regulating several oncogenes including KRAS. A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC. [...]
2015 - 10.1093/annonc/mdv285
Annals of oncology, Vol. 26, Issue 9 (September 2015) , p. 1936-1941  
Registre complet - Creative Commons
15.
8 p, 207.5 KB Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS -mutated metastatic colorectal cancer / Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ; Cervantes, Andrés (Universitat de València. Biomedical Research Institute) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Roselló, Susana (Universitat de València. Biomedical Research Institute) ; Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Tejpar, Sabine (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Prenen, H. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Martinelli, E. (Second University of Naples. Department of Experimental and Clinical Medicine) ; Troiani, T. (Second University of Naples. Department of Experimental and Clinical Medicine) ; Laffranchi, B. (Merck Serono SA) ; Jego, V (Merck Serono SA) ; von Richter, O. (Merck KGaA) ; Ciardiello, Fortunato (Second University of Naples. Department of Experimental and Clinical Medicine) ; Universitat Autònoma de Barcelona
The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents such as pimasertib. [...]
2015 - 10.1038/bjc.2015.144
British Journal of Cancer, Vol. 112 (June 2015) , p. 1874-1881  
Registre complet - Creative Commons
16.
325 p, 1.8 MB Closing circles: the construction of mother archetypes in five novels by Doris Lessing / Casablancas i Cervantes, Anna ; Monnickendam, Andrew, dir. ; Universitat Autònoma de Barcelona. Departament de Filologia Anglesa i de Germanística
Aquesta tesi investiga la construcció i desenvolupament dels personatges femenins a ĺobra de Doris Lessing, considerant especialment la relació personal que estableixen amb el concepte de maternitat. [...]
The present thesis investigates the construction and development of Doris Lessing's female characters, taking into account their personal relationship with their potential motherhood. Chapter 1 offers a review of the different approaches to the writing of Doris Lessing, as well as an overview of its cultural and theoretical background, focusing on psychoanalysis and feminism, and, most especially, on Jungian and Lacanian psychoanalysis, and post-Lacanian feminism. [...]
[Barcelona] : Universitat Autònoma de Barcelona, 2016  
Registre complet - Creative Commons
17.
171 p, 7.4 MB Estudi ambiental de la proposta del POUM de Viver i Serrateix / Sangrà Cervantes, Albert ; Molina Gallart, David, dir. (Universitat Autònoma de Barcelona. Departament de Geografia) ; Universitat Autònoma de Barcelona. Facultat de Ciències
L'objecte d'aquest estudi és fer una anàlisi ambiental de la proposta del Pla d'Ordenació Urbanística Municipal del municipi de Viver i Serrateix, i poder presentar en darrer terme, una alternativa al model estudiat, que pugui oferir uns criteris basats en un model més sostenible i respectuós amb l'entorn, i coherent amb la realitat existent.
Nota: Aquest document conté originàriament altre material i/o programari només consultable a la Biblioteca de Ciència i Tecnologia.
2007
5 documents
Registre complet - Creative Commons
18.
5 p, 189.1 KB Influencia del conocimiento del resultado numérico en la resolución de problemas / Perales Palacios, F. Javier ; Cervantes Madrid, A.
1984 - 10.5565/rev/ensciencias.5324
Enseñanza de las ciencias, V. 2 n. 2 (1984) p. 97-101  
Registre complet - Creative Commons
19.
5 p, 184.8 KB Bases de dades [21288] / Lladós, Josep (Universitat Autònoma de Barcelona. Departament de Ciències de la Computació) ; Cervantes, Anton ; Mas, Joan ; Universitat Autònoma de Barcelona. Escola Universitària d'Informàtica
2005-06
Enginyer Tècnic en Informàtica de Gestió [459]
Enginyer Tècnic en Informàtica de Sistemes [463]  
Registre complet - Creative Commons

Dipòsit Digital de Documents de la UAB : 19 registres trobats   anterior11 - 19  anar al registre:
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem